LIN9
Summary: This gene encodes a tumor suppressor protein that inhibits DNA synthesis and oncogenic transformation through association with the retinoblastoma 1 protein. The encoded protein also interacts with a complex of other cell cycle regulators to repress cell cycle-dependent gene expression in non-dividing cells. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jul 2012].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| lin-9 DREAM MuvB core complex component | MIM:609375 | Ensembl:ENSG00000183814 | HGNC:HGNC:30830 | PA134970771 | 1q42.12 |
Gene Categories:
TUMOR SUPPRESSORGO terms in LIN9
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | IBA | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IEA | GO:0017053 | transcriptional repressor complex |
| BP | IBA | GO:0000003 | reproduction |
| BP | IEA | GO:0006351 | transcription, DNA-templated |
| BP | IBA | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0007049 | cell cycle |
| BP | IBA | GO:0051726 | regulation of cell cycle |
| BP | TAS | GO:0051726 | regulation of cell cycle |
| BP | IEA | GO:0071897 | DNA biosynthetic process |
| MF | IBA | GO:0003677 | DNA binding |
| MF | IPI | GO:0005515 | protein binding |
Gene expression in normal tissue: LIN9
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in LIN9
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1362300 | Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-156711 | Polo-like kinase mediated events |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-453274 | Mitotic G2-G2/M phases |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-539107 | Activation of E2F1 target genes at G1/S |
| reactome | R-HSA-69202 | Cyclin E associated events during G1/S transition |
| reactome | R-HSA-69205 | G1/S-Specific Transcription |
| reactome | R-HSA-69206 | G1/S Transition |
| reactome | R-HSA-69242 | S Phase |
| reactome | R-HSA-69275 | G2/M Transition |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
| reactome | R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry |
| wikipathways | WP2361 | Gastric Cancer Network 1 |
| kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD705 | Nakiterpiosin | 6 |
| iGMDRD255 | SB225002 | 3 |
| iGMDRD260 | FQI-2 | 3 |
| iGMDRD138 | PX 12 | 6 |
| iGMDRD251 | ML162 | 3 |
| iGMDRD246 | NPC26 | 3 |
| iGMDRD64 | Parbendazole | 6 |
| iGMDRD886 | Compound 1541A | 3 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD414 | MST-312 | 6 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD484 | Pluripotin | 3 |
| iGMDRD144 | NSC95397 | 6 |
| iGMDRD150 | RITA | 3 |
| iGMDRD889 | Compound 7d-cis | 6 |
| iGMDRD883 | CIL55A | 4 |
| iGMDRD945 | ML214 | 6 |
| iGMDRD280 | CYTOCHALASIN B | 9 |
| iGMDRD193 | Fqi1 | 6 |
| iGMDRD446 | LY 2183240 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in LIN9
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.